Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Roche Leads Biotechnology Industry With An Unprecedented Growth Of Nearly 100%, While Geron, Nanosphere And Ultra Biotech Jump Into The Top 10 Patent

Abstract:
According to The Patent Board's Biotechnology Patent Scorecard published in The Wall Street Journal, Roche's top billing is due to their ownership in Genentech.

Roche Holding Ltd remains the leader for the Biotechnology Scorecard, with an unprecedented Science Strength (SS) that grew by almost 100% this past quarter. Their lead is primarily due to majority owned subsidiary and biotech, Genentech, who account for approximately 80% of the patents represented. Geron Corp, known for stem cell research has soared into the top 10 moving up 7 spots to sit in 5th position with an increase in SS™ of 77%. There are two other newcomers to the top 10, one of which is Nanosphere Inc, who is bringing the combination of nanotechnology and molecular diagnostics into the marketplace. The other is little known Ultra Biotech Ltd which utilizes electromagnetic energy for culturing biotechnology compositions.

Eight of the top 10 companies have above average Research Intensity (RI), which measures the degree of scientific referencing for their most recent patenting compared to others in the industry. The largest increases in Research Intensity™ this quarter came from 1st and 2nd ranked, Roche (52%) and Invitrogen (23%), while newcomers Geron and Nanosphere have the highest scores among the top 10 of 3.43 and 3.29 respectively. They are both referencing well known publications such as Proceedings of the National Academy of Science and The Journal of Biological Chemistry; however Nanosphere is also highly referencing the interdisciplinary journal, Langmuir, further showing its differentiation in the marketplace. Another company who is highly referencing Langmuir is Affymetrix, ranked 18th (not charted) who pioneered the use of semiconductors and combinatorial chemistry for biotechnology use. Despite dropping a spot each this quarter, both Isis Pharmaceuticals Inc and Biogen Idec Inc have RI scores twice the industry average.


Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Materials for the next generation of electronics and photovoltaics: MacArthur Fellow develops new uses for carbon nanotubes October 21st, 2014

Special UO microscope captures defects in nanotubes: University of Oregon chemists provide a detailed view of traps that disrupt energy flow, possibly pointing toward improved charge-carrying devices October 21st, 2014

Super stable garnet ceramics may be ideal for high-energy lithium batteries October 21st, 2014

Could I squeeze by you? Ames Laboratory scientists model molecular movement within narrow channels of mesoporous nanoparticles October 21st, 2014

Announcements

Special UO microscope captures defects in nanotubes: University of Oregon chemists provide a detailed view of traps that disrupt energy flow, possibly pointing toward improved charge-carrying devices October 21st, 2014

Super stable garnet ceramics may be ideal for high-energy lithium batteries October 21st, 2014

Could I squeeze by you? Ames Laboratory scientists model molecular movement within narrow channels of mesoporous nanoparticles October 21st, 2014

Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions October 21st, 2014

Patents/IP/Tech Transfer/Licensing

Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014

Aculon Receives Patent for Application of Enhanced Bonding Layers on Titanium October 9th, 2014

harmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific: PharmaEngine to make milestone payment to Nanobiotix in October 2014 to recognize the value created October 8th, 2014

‘Small’ transformation yields big changes September 16th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE